Ga-68 PSMA PET-CT in Initial Staging First Line Imaging of Prostate Cancer: The Clinical Impact of Oligometastatic Disease

Yıl 2022, Cilt: 2 Sayı: 2, 15 - 24, 01.08.2022

Pınar Pelin Özcan Zehra Pınar Koç Vehbi Erçolak Zeynep Selcan Sağlam Gökçe Yavan Murat Bozlu Mesut Tek Erdem Akbay

Öz

Background: Imaging plays an essential role in the evaluation of prostate cancer patients. In recent years, much attention has been focused on 68Ga-PSMA PET-CT in prostate cancer patients and has been widely used for staging, especially biochemical relapse-restaging and therapy response for these patients. This study aimed to evaluate 68 Ga PSMA PET-CT imaging in initial staging-first line imaging of prostate cancer from low to high risk patients.
Materials & Methods: Patients with low, intermediate and high risk newly diagnosed prostate cancer referred for initial staging of prostate cancer were included in the study. Histopathology and follow-up clinical and radiological information after PET/CT scanning served as the standard of reference.
Results: The study included a total of 176 consecutive patients underwent 68 Ga PSMA PET-CT for initial staging with prostate cancer final histopathology result. The study included a total of 27 low-risk, 35 intermediate risk, and 114 high-risk patients SUVmax in the primary tumor was correlated significantly with PSA levels and patient risk group. Mean SUVmax values of the primary prostate lesion were 16.6 %, 25.8 % and 35.2 % in low, intermediate and high risk patients, respectively. Oligometastases were detected in low and intermediate groups in similar proportions and slightly less in high risk patients (22 %, 22.8 % and 15.7 % in low, intermediate and high risk patients respectively), In contrast, in low, intermediate, and high-risk patients, multiple metastases were detected significantly higher in high-risk group patients (3.7 %, 8.6 %, and 52.6 %, respectively).
Conclusions: Oligometastases were detected with a relatively high rate in low- and intermediate-risk group patients. Ga-68 PSMA PET-CT imaging in newly diagnosed prostate cancer patients, even in low-risk patients, was quite valuable in the current studyGa-68 PSMA imaging should be done in all risk groups as a first-line imaging modality. This finding should be supported by other studies with the large number of patients.

Anahtar Kelimeler

68 Ga PSMA PET-CT, Prostate Cancer, Initial Staging

Kaynakça

• 1. Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016). Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European urology, 70(6), 926–937. https://doi.org/10.1016/j.eururo.2016.06.021
• 2. Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., Matveev, V. B., Moldovan, P. C., van den Bergh, R., Van den Broeck, T., van der Poel, H. G., van der Kwast, T. H., Rouvière, O., Schoots, I. G., … Cornford, P. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology, 71(4), 618–629. https://doi.org/10.1016/j.eururo.2016.08.003
• 3. Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., Mottet, N., & European Association of Urology (2014). EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology, 65(1), 124–137. https://doi.org/10.1016/j.eururo.2013.09.046
• 4. Larson, S. M., Morris, M., Gunther, I., Beattie, B., Humm, J. L., Akhurst, T. A., Finn, R. D., Erdi, Y., Pentlow, K., Dyke, J., Squire, O., Bornmann, W., McCarthy, T., Welch, M., & Scher, H. (2004). Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 45(3), 366–373
• 5. Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H. J., Heck, M., Kübler, H., Beer, A. J., Schwaiger, M., & Eiber, M. (2016). Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. The Journal of urology, 195(5), 1436–1443. https://doi.org/10.1016/j.juro.2015.12.025
• 6. Dewes, S., Schiller, K., Sauter, K., Eiber, M., Maurer, T., Schwaiger, M., Gschwend, J. E., Combs, S. E., & Habl, G. (2016). Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiation oncology (London, England), 11, 73. https://doi.org/10.1186/s13014-016-0646-2
• 7. Shakespeare T. P. (2015). Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiation oncology (London, England), 10, 233. https://doi.org/10.1186/s13014-015-0548-8
• 8. Roach, P. J., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q. A., Thompson, B. D., Cusick, T., McCarthy, M., Tang, C., Ho, B., Stricker, P. D., & Scott, A. M. (2018). The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(1), 82–88. https://doi.org/10.2967/jnumed.117.197160
• 9. Fendler, W. P., Schmidt, D. F., Wenter, V., Thierfelder, K. M., Zach, C., Stief, C., Bartenstein, P., Kirchner, T., Gildehaus, F. J., Gratzke, C., & Faber, C. (2016). 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 57(11), 1720–1725. https://doi.org/10.2967/jnumed.116.172627
• 10. Kuten, J., Mabjeesh, N. J., Lerman, H., Levine, C., Barnes, S., & Even-Sapir, E. (2019). Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer. The Israel Medical Association journal : IMAJ, 21(2), 100–104
• 11. Sweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998). Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 52(4), 637–640. https://doi.org/10.1016/s0090-4295(98)00278-7
• 12. Agus, D. B., Golde, D. W., Sgouros, G., Ballangrud, A., Cordon-Cardo, C., & Scher, H. I. (1998). Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer research, 58(14), 3009–3014
• 13. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B., & Bander, N. H. (1997). Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer research, 57(17), 3629–3634
• 14. Herlemann, A., Wenter, V., Kretschmer, A., Thierfelder, K. M., Bartenstein, P., Faber, C., Gildehaus, F. J., Stief, C. G., Gratzke, C., & Fendler, W. P. (2016). 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. European urology, 70(4), 553–557. https://doi.org/10.1016/j.eururo.2015.12.051
• 15. Hijazi, S., Meller, B., Leitsmann, C., Strauss, A., Meller, J., Ritter, C. O., Lotz, J., Schildhaus, H. U., Trojan, L., & Sahlmann, C. O. (2015). Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. The Prostate, 75(16), 1934–1940. https://doi.org/10.1002/pros.23091
• 16. Pyka, T., Okamoto, S., Dahlbender, M., Tauber, R., Retz, M., Heck, M., Tamaki, N., Schwaiger, M., Maurer, T., & Eiber, M. (2016). Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. European journal of nuclear medicine and molecular imaging, 43(12), 2114–2121. https://doi.org/10.1007/s00259-016-3435-0
• 17. Giesel, F. L., Fiedler, H., Stefanova, M., Sterzing, F., Rius, M., Kopka, K., Moltz, J. H., Afshar-Oromieh, A., Choyke, P. L., Haberkorn, U., & Kratochwil, C. (2015). PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. European journal of nuclear medicine and molecular imaging, 42(12), 1794–1800. https://doi.org/10.1007/s00259-015-3106-6
• 18. Budäus, L., Leyh-Bannurah, S. R., Salomon, G., Michl, U., Heinzer, H., Huland, H., Graefen, M., Steuber, T., & Rosenbaum, C. (2016). Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. European urology, 69(3), 393–396. https://doi.org/10.1016/j.eururo.2015.06.010
• 19. Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., Wong, L. M., Taubman, K., Ting Lee, S., Hsiao, E., Roach, P., Nottage, M., Kirkwood, I., Hayne, D., Link, E., Marusic, P., … proPSMA Study Group Collaborators (2020). Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet (London, England), 395(10231), 1208–1216. https://doi.org/10.1016/S0140-6736(20)30314-7
• 20. Barakat, A., Yacoub, B., Homsi, M. E., Saad Aldine, A., El Hajj, A., & Haidar, M. B. (2020). Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer. Scientific reports, 10(1), 2705. https://doi.org/10.1038/s41598-020-59296-6
• 21. Donswijk, M. L., van Leeuwen, P. J., Vegt, E., Cheung, Z., Heijmink, S., van der Poel, H. G., & Stokkel, M. (2020). Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. BMC cancer, 20(1), 723. https://doi.org/10.1186/s12885-020-07192-7
• 22. Asli Ayan, Sumeyye Alkan and Bengul Gunalp. The Value of Ga-68 PSMA PET /CT in Primary Staging of Prostate Cancer. Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1450.